Alpha Or Leukocyte Patents (Class 424/85.7)
-
Patent number: 8597634Abstract: The present invention relates to interferon (IFN)-?2a modified at a specific Lys residue with Y-shaped branched polyethylene glycol (PEG) derivative and the preparation thereof, as well as the use of the prepared IFN-?2a modified by PEG at a single amino acid residue in medicines.Type: GrantFiled: September 4, 2007Date of Patent: December 3, 2013Assignee: Biosteed Gene Expression Tech. Co., Ltd.Inventors: Weidong Zhou, Qingjiang Xiao, Li Sun, Tiebing Wang, Bin Liu, Song Lin, Min Liu, Fenghong Yin, Lu Zhuang, Lifang Lei
-
Publication number: 20130315868Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Inventors: Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART
-
Publication number: 20130315864Abstract: The present invention provides nucleoside phosphoramidate compounds of Formula I, where R1, R2a, R2b, R3, R4, R5a, R5b, R6, R7, R8a, R8b, M and W are as defined herein. The invention further includes pharmaceutical compositions comprising a compound of Formula I, methods of use of these compounds for treating a viral infection, and methods of producing these compounds.Type: ApplicationFiled: May 17, 2013Publication date: November 28, 2013Applicant: ENANTA PHARMACEUTICALS, INC.Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang
-
Publication number: 20130315866Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Inventors: Christophe Claude PARSY, Francois-Rene ALEXANDRE, Cyril B. DOUSSON, David DUKHAN, Claire PIERRA, Dominique SURLERAUX, Benjamin Alexander MAYES, Adel M. MOUSSA, Alistair James STEWART
-
Publication number: 20130315867Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 21, 2013Publication date: November 28, 2013Inventors: Christophe Claude PARSY, Francois-Rene ALEXANDRE, Cyril B. DOUSSON, David DUKHAN, Gilles GOSSELIN, Houcine RAHALI, Dominique SURLERAUX
-
Patent number: 8591878Abstract: A class of macrocyclic compounds of formula (I), wherein R1, R3, R4, Ra, Rb, A, B, Z, M, W and n are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection.Type: GrantFiled: February 12, 2009Date of Patent: November 26, 2013Assignees: Merck Sharp & Dohme Corp., Istituto di Ricerche di Biologia Molecolare P. Angeletti SpaInventors: John A. McCauley, Nigel J. Liverton, Steven Harper, Charles J. McIntyre, Michael T. Rudd
-
Publication number: 20130309200Abstract: New imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: November 24, 2011Publication date: November 21, 2013Applicant: ALMIRALL, S.A.Inventors: Jacob Gonzalez Rodriguez, Bernat Vidal Juan, Laura Vidal Gispert, Jordi Bach Taña
-
Publication number: 20130309201Abstract: It is disclosed a pharmaceutical composition containing an oligonuclelotide chelate complex and at least one polypeptide or pegylated polypeptide. The present disclosure also describes additional pharmaceutical compositions and methods for the treatment of diseases including viral infections.Type: ApplicationFiled: May 17, 2013Publication date: November 21, 2013Inventors: Michel BAZINET, Andrew VAILLANT
-
Publication number: 20130309202Abstract: The present invention provides methods to improve liver function utilizing tocotrienols. In particular, various liver pathologies may be treated using the present methods, including cirrhosis, hepatitis, and sclerosing cholangtitis. The present invention also provides methods to increase tissue concentrations of tocotrienols.Type: ApplicationFiled: May 20, 2013Publication date: November 21, 2013Applicant: The Ohio State UniversityInventors: Chandan K. Sen, Cameron L. Rink, Sashwati Roy, Savita Khanna
-
Publication number: 20130302275Abstract: Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.Type: ApplicationFiled: December 28, 2012Publication date: November 14, 2013Inventors: Ge Wei, H. Michael Shepard, Qiping Zhao, Robert James Connor
-
Publication number: 20130302282Abstract: A class of compounds that inhibit Hepatitis C Virus (HCV) is disclosed, along with compositions containing the compound, and methods of using the composition for treating individuals infected with HCV.Type: ApplicationFiled: October 21, 2011Publication date: November 14, 2013Applicant: Presidio Pharmaceuticals, Inc.Inventors: Min Zhong, Leping Li
-
Publication number: 20130295045Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: ApplicationFiled: June 17, 2013Publication date: November 7, 2013Inventors: Kenya SHITARA, Rinpei NIWA, So OHTA, Yuka SASAKI, Junji KANAZAWA, Toshihiko ISHII, Shiro AKINAGA
-
Publication number: 20130295052Abstract: The present invention relates to a novel drug delivery system comprising a drug(s)-protein-polymer triple conjugate. The triple conjugate employs a (i) protein moiety capable of binding selectively to a particular target site possessed by a cell/affected organ, (ii) a polymer moiety, covalently linked to the protein and (iii) an active drug moiety that includes one or more drug(s) covalently linked to either said polymer moiety or to a protein moiety. The conjugates of the present invention have target specificity and better selectivity to a defined population of cells/organs(s). The present invention further relates to methods of preparation and methods of treatment comprising administering said conjugate as a single unit. The conjugates of the present invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic applications.Type: ApplicationFiled: November 21, 2011Publication date: November 7, 2013Inventor: Manu Chaudhary
-
Publication number: 20130295005Abstract: Disclosed are compositions and methods comprising combinations of anti-CD74 antibodies with a therapeutic agent that is attached to the anti-CD74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from CD74, such as CD19, CD20, CD21, CD22, CD23, CD37, CD40, CD40L, CD52, CD80, IL-6, CXCR4 or HLA-DR. However, the therapeutic agent may be an immunomodulator, a cytokine, a toxin or other known therapeutic agent. Preferably, the anti-CD74 antibody is part of a DNL complex. More preferably, combination therapy with the anti-CD74 antibody and therapeutic agent is more effective than antibody alone, therapeutic agent alone, or the combination of unconjugated anti-CD74 antibody and therapeutic agent. Administration of combination induces apoptosis of target cells in diseases in which CD74 is overexpressed, such as solid tumors, B-cell lymphomas or leukemias, autoimmune disease, immune dysfunction disease or diabetes.Type: ApplicationFiled: May 29, 2013Publication date: November 7, 2013Inventors: Chien-Hsing Chang, David M. Goldenberg, Edmund A. Rossi
-
Publication number: 20130295051Abstract: The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below.Type: ApplicationFiled: September 2, 2011Publication date: November 7, 2013Inventors: Kenneth W. Bair, Alexandre J. Buckmelter, Bingsong Han, Jian Lin, Dominic J. Reynolds, Chase C. Smith, Zhongguo Wang, Xiaozhang Zheng
-
Publication number: 20130295042Abstract: This invention provides novel active agents (e.g. peptides, small organic molecules, amino acid pairs, etc.) peptides that ameliorate one or more symptoms of eye disease and/or other pathologies characterized by an inflammatory response. In certain embodiment, the peptides resemble a G* amphipathic helix of apolipoprotein J. The agents are highly stable and readily administered via an oral route or via intraocular injection.Type: ApplicationFiled: March 14, 2013Publication date: November 7, 2013Inventors: Gattadahalli M. Anantharamaiah, Martin Rudolph, Alan M. Fogelman, Mohamad Navab
-
Publication number: 20130295043Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in an elderly patient preferably exhibiting an age of at least 50 years, more preferably of at least 55 years, 60 years, 65 years, 70 years, or older, wherein the treatment comprises vaccination of the patient and eliciting an immune response in said patient. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.Type: ApplicationFiled: February 29, 2012Publication date: November 7, 2013Applicant: CUREVAC GMBHInventors: Karl-Josef Kallen, Thomas Kramps, Margit Schnee, Benjamin Petsch, Lothar Stitz
-
Publication number: 20130295050Abstract: DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.Type: ApplicationFiled: September 14, 2012Publication date: November 7, 2013Applicant: IMMUNOGEN, INC.Inventors: Rajeeva SINGH, Daniel J. TAVARES, Nancy E. DAGDIGIAN
-
Publication number: 20130295049Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 30, 2012Publication date: November 7, 2013Applicant: ENANTA PHARMACEUTICALS, INCInventor: ENANTA PHARMACEUTICALS, INC
-
Patent number: 8574563Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: GrantFiled: September 11, 2012Date of Patent: November 5, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. St. Laurent, Fukang Yang, David R. Langley, Gan Wang, Lawrence G. Hamann
-
Publication number: 20130287733Abstract: IFN-alpha mutants are obtained by substituting Cys for Tyr at position 85 or 86 in existing IFN-alpha. Their polyethylene glycol derivatives with high in vitro antiviral activity and prolonged in vivo half-life are also provided, wherein a polyethylene glycol moiety is covalently bound to the free Cys residue of an IFN-alpha mutant. The preparation methods of PEG derivatives of IFN-alpha mutants and medical compositions comprising the derivatives are also provided. The test results showed that the IFN-alpha mutants of the present invention are ready to prepare and have high activity; their polyethylene glycol derivatives have extended lifetime in the body and low clearance rate.Type: ApplicationFiled: March 27, 2012Publication date: October 31, 2013Applicants: BEIJING BIO-TECH DEVELOPMENT CO., LTD., BEIJING TRI-PRIME GENETIC ENGINEERING CO., LTD.Inventors: Jinyi LIU, Xiaoxia NIU, Minyi ZHOU, Yi YANG, Jianbo SUN, Yongqing CHENG
-
Publication number: 20130287734Abstract: Disclosed is a liquid formulation in which a long-acting INF? conjugate that has improved in vivo duration and stability can be stored stably for a long period of time. It comprises a stabilizer comprising a buffer, a sugar alcohol, a non-ionic surfactant and an isotonic agent. Being free of human serum albumin and other potential factors harmful to the body, the liquid formulation is free of concerns about viral infections and guarantees excellent storage stability to long-acting INF? conjugates.Type: ApplicationFiled: October 26, 2011Publication date: October 31, 2013Applicant: HANMI SCIENCE CO., LTD.Inventors: Dae Seong Im, Jae Min Lee, Jong Soo Lee, Sung Min Bae, Se Chang Kwon
-
Publication number: 20130280214Abstract: The present invention relates to Polycyclic Heterocycle Derivatives, such as compound 1: (1) compositions comprising the Polycyclic Heterocycle Derivatives, and methods of using the Polycyclic Heterocycle Derivatives for treating or preventing HCV infection in a patient.Type: ApplicationFiled: September 28, 2011Publication date: October 24, 2013Applicant: Merck Sharp & Dohme Corp.Inventors: Joseph P. Vacca, Craig A. Coburn, David B. Olsen, Joseph A. Kozlowski, Stuart B. Rosenblum
-
Publication number: 20130280211Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.Type: ApplicationFiled: June 17, 2013Publication date: October 24, 2013Inventors: Carol Bachand, Makonen Belema, Daniel H. Deon, Andrew C. Good, Jason Goodrich, Clint A. James, Rico Lavoie, Omar D. Lopez, Alain Martel, Nicholas A. Meanwell, Van N. Nguyen, Jeffrey Lee Romine, Edward H. Ruediger, Lawrence B. Snyder, Denis R. ST. Laurent, Fukang Yang, David R. Langley, Lawrence G. Hamann
-
Publication number: 20130280210Abstract: Disclosed herein are methods of inhibiting proliferation of a cancer cell or inducing apoptosis of a cancer cell, which does not overexpress N—CoR. Also disclosed herein are methods of inhibiting proliferation or inducing apoptosis of a cancer cell that overexpresses TCTP and methods for determining whether a compound is effective in inducing cell death.Type: ApplicationFiled: April 25, 2013Publication date: October 24, 2013Inventor: John S. Kovach
-
Publication number: 20130273005Abstract: This invention relates to combinations of therapeutic molecules useful for treating hepatitis C virus infection. The present invention relates to methods, uses, dosing regimens, and compositions.Type: ApplicationFiled: December 8, 2011Publication date: October 17, 2013Applicant: GILEAD SCIENCES, INC.Inventors: William E. Delaney, John O. Link, Hongmei Mo, David W. Oldach, Adrian S. Ray, William J. Watkins, Cheng Yong Yang, Weidong Zhong
-
Publication number: 20130266538Abstract: The present application relates to solid state forms, for example, crystalline forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2?-C-methyluridine-5?-(O-phenyl-N—(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.Type: ApplicationFiled: March 11, 2013Publication date: October 10, 2013Inventors: Anuj K. Kuldipkumar, Ales Medek, Lori Ann Ferris, Praveen Mudunuri, Young Chun Jung, David Richard Willcox, Michael Waldo, William Aloysius Nugent
-
Patent number: 8551469Abstract: This invention provides a recombinant interferon (rSIFN-co) and its equivalent with changed spatial configuration, high efficacy and low side effects. Therefore, high dose of rSIFN-co may be used. The cytotoxic effect of rSIFN-co is only one-eighth (?) of currently clinically available interferons but its anti-viral effect is approximately five to twenty (5-20) times higher, and when used in vivo it has a broader spectrum of clinical applications and longer biofeedback response. This invention further provides methods of using the recombinant interferon to treat proliferative disorders such as cancer or viral diseases.Type: GrantFiled: October 6, 2008Date of Patent: October 8, 2013Assignee: Superlab Far East LimitedInventor: Guangwen Wei
-
Patent number: 8551468Abstract: A composition including a surfactant and at least one alkyl glycoside and/or saccharide alkyl ester and a drug. The surfactant composition(s) when admixed with a drug is non-toxic and non-irritating, while stabilizing and increasing the bioavailability of the drug. The invention also provides compositions that enhance absorption of drugs via the oral, ocular, nasal, nasolacrimal, inhalation or pulmonary, oral cavity (sublingual or Buccal cell) or CSF delivery route of a patient, including but not limited to insulin, glucagon and exendin-4.Type: GrantFiled: August 11, 2008Date of Patent: October 8, 2013Assignee: Aegis Therapeutics LLCInventor: Edward T. Maggio
-
Publication number: 20130259907Abstract: The present disclosure provides a biodegradable drug delivery composition including a vehicle and an insoluble component comprising beneficial agent dispersed in the vehicle. Typically, the composition is not an emulsion, but has a low viscosity and further provides for minimized initial burst and sustained release of the beneficial agent over time. Also provided, are kits including the biodegradable drug delivery composition or components thereof, as well as methods of making and using the biodegradable drug delivery composition.Type: ApplicationFiled: March 7, 2013Publication date: October 3, 2013Inventors: William van Osdol, Su Il Yum, Felix Theeuwes, Michael Sekar, John W. Gibson, Keith E. Branham, Huey-Ching Su
-
Publication number: 20130259832Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit Hepatitis C virus (HCV), compositions comprising such compounds, and methods for treating Hepatitis C using such combinations.Type: ApplicationFiled: March 11, 2013Publication date: October 3, 2013Inventors: Julie A. Lemm, Stacey A. Voss, Min Gao, Susan E. Chaniewski, Amy K. Sheaffer, Fiona McPhee
-
Patent number: 8545832Abstract: The present invention relates to pre-formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The preformulations are suitable for generating parenteral, non-parenteral and topical depot compositions for sustained release of active agents. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: June 29, 2012Date of Patent: October 1, 2013Assignee: Camarus ABInventors: Krister Thuresson, Fredrik Tiberg, Markus Johansson, Ian Harwigsson, Fredrik Joabsson, Markus Johnsson
-
Publication number: 20130251678Abstract: The invention concerns the use of cyclophilin inhibitors in the treatment of Hepatitis C virus infection.Type: ApplicationFiled: November 29, 2011Publication date: September 26, 2013Applicant: NOVARTIS AGInventor: Claudio Avila
-
Publication number: 20130251677Abstract: The present invention provides genetic markers on human chromosome 19 that are associated with a beneficial response to interferon alpha (IFN-?). These IFN-? response markers are useful, inter alia, to identify patients who are most likely to benefit from treatment with IFN-? pharmaceutical compositions and drug products, in methods of treating patients having a disease susceptible to treatment with an IFN-?, and in methods for selecting the most appropriate therapy for such patients.Type: ApplicationFiled: May 30, 2013Publication date: September 26, 2013Applicant: Merck Sharp & Dohme Corp.Inventors: Arthur Bertelsen, Jacques Fellay, Dongliang Ge, David B. Goldstein, John G. McHutchison, Ping Qiu, Kevin Shianna, Jason S. Simon, Alexander J. Thompson, Thomas Urban
-
Publication number: 20130251676Abstract: A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity; and domain (b) which is a sequence of an immunostimulating effector peptide, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.Type: ApplicationFiled: December 5, 2011Publication date: September 26, 2013Applicant: ADAMED SP. Z O.O.Inventors: Jerzy Szczepan Pieczykolan, Krzysztof Kazimierz Lemke, Sebastian Pawlak, Bartlomiej Zerek
-
Publication number: 20130243866Abstract: A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in ?-sheet structure dominant silk microsphere structures having about 2 ?m in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.Type: ApplicationFiled: May 7, 2013Publication date: September 19, 2013Applicant: TRUSTEES OF TUFTS COLLEGEInventors: David L. KAPLAN, Xiaoqin WANG
-
Publication number: 20130243727Abstract: Provided herein are triazole FASN inhibitors of the formula (I): or a pharmaceutically acceptable form thereof; wherein the variables RA, X, RB, and RC are defined herein. Also provided herein are pharmaceutical compositions of the compounds provided herein as well as methods of their use for the treatment of various disorders such as hyperproliferative disorders, inflammatory disorders, obesity-related disorders and microbial infections.Type: ApplicationFiled: April 29, 2013Publication date: September 19, 2013Applicant: INFINITY PHARMACEUTICALS, INC.Inventors: Adilah BAHADOOR, Alfredo C. CASTRO, Lawrence K. CHAN, Gregg F. KEANEY, Marta NEVALAINEN, Vesa NEVALAINEN, Stephane PELUSO, Thomas T. TIBBITTS
-
Patent number: 8535657Abstract: The present invention is related to stable pharmaceutical formulations to be applied by parenteral (liquids or freeze-dried), or topic way (gel, unguent or cream) that contain different quantities of the recombinant interferons gamma and alpha in synergistic proportions for the treatment of pathological events that contemplate the malignant or benign not-physiological growth of cells in tissue or organs.Type: GrantFiled: October 27, 2006Date of Patent: September 17, 2013Assignee: Centro de Ingenieria Genetica y BiotecnologiaInventors: Iraldo Bello Rivero, Pedro Lopez Saura, Yanelda Garcia Vega, Hector Santana Milian, Ana Aguilera Barreto, Rolando Paez Meireles, Lorenzo Anasagasti Angulo
-
Publication number: 20130236550Abstract: Microparticles consisting of (a) a matrix with a mixture of (a1)) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation.Type: ApplicationFiled: April 26, 2013Publication date: September 12, 2013Applicant: NOVARTIS AGInventors: Michael Ausborn, Olivier Lambert, Oskar Nagele
-
Patent number: 8529882Abstract: The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel stereoselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.Type: GrantFiled: July 3, 2012Date of Patent: September 10, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Robert Edward Babine, Shu Hui Chen, Ivan Collado, Cristina Garcia-Paredes, John Irvin Glass, Ling Jin, Jason Eric Lamar, Raymond Samuel Parker, III, Nancy June Snyder, Xicheng David Sun, Deqi Guo, Yvonne Yee Mai Yip, Q. May Wang, Frantz Victor, Mark Joseph Tebbe, Robert B. Perni, Luc Farmer
-
Publication number: 20130230488Abstract: The invention relates to an immunity-inducing agent comprising, as an active ingredient, at least one polypeptide having immunity-inducing activity that is selected from among polypeptides (a), (b), and (c): (a) a polypeptide of at least seven contiguous amino acids of the amino acid sequence shown by any even SEQ ID number selected from SEQ ID NOs: 2 to 30 listed in the Sequence Listing; (b) a polypeptide of at least seven amino acids having 90% or more sequence identity with the polypeptide (a); and (c) a polypeptide comprising the polypeptide (a) or (b) as a partial sequence thereof, or a recombinant vector comprising a polynucleotide encoding said polypeptide and capable of expressing said polypeptide in vivo.Type: ApplicationFiled: May 6, 2013Publication date: September 5, 2013Applicant: Toray Industries, Inc.Inventors: Fumiyoshi OKANO, Masaki SHIMIZU, Takanori SAITO
-
Publication number: 20130224147Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.Type: ApplicationFiled: January 10, 2013Publication date: August 29, 2013Applicant: Idenix Pharmaceuticals, Inc.Inventor: Idenix Pharmaceuticals, Inc.
-
Publication number: 20130224283Abstract: A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.Type: ApplicationFiled: March 22, 2013Publication date: August 29, 2013Applicant: HELIX BIOPHARMA CORP.Inventors: Marianna FOLDVARI, Praveen KUMAR, John M. DOCHERTY
-
Publication number: 20130224152Abstract: Compounds, methods, and compositions for the treatment of infections in or exposure to humans and other host animals of Flaviviridae viruses, including HCV, that includes the administration of an effective amount of a spiro[2.4]heptane as described herein or a pharmaceutically acceptable salt or prodrug thereof, optionally in a pharmaceutically acceptable carrier, are provided. The spiro[2.4]heptane compounds either possess antiviral activity, or are metabolized to a compound that exhibits such activity.Type: ApplicationFiled: February 14, 2013Publication date: August 29, 2013Applicant: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventor: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.
-
Patent number: 8518879Abstract: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of using such compositions and kits comprising the skin cream therein.Type: GrantFiled: March 4, 2011Date of Patent: August 27, 2013Inventor: Ahmed H. Al-Qahtani
-
Publication number: 20130216498Abstract: New imidazopyridine derivatives having the chemical structure of formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).Type: ApplicationFiled: December 23, 2010Publication date: August 22, 2013Inventors: Paul Robert Eastwood, Jacob Gonzales Rodriguez, Jordi Bach Taña, Lluis Miquel Pages Santacana, Joan Taltavull Moll, Juan Francisco Caturla Javaloyes, Victor Giulio Matassa
-
Publication number: 20130216610Abstract: A biphasic lipid vesicle composition for treating cervical displasia by intravaginal delivery. The composition includes a suspension of lipid-bilayer vesicles having entrapped therein, an oil-in-water emulsion, human interferon alpha-2b and L-methionine, the composition having an interferon alpha-2b specific activity of between about 1-10 MIU (million international units) per gram composition, and between 0.01 to 0.5 weight percent L-methionine. In the treatment method, the composition is administered at a dose of between about 1-20 MIU interferon alpha-2b, and this dose is administered at least 3 days/week, for a period of at least 4 weeks.Type: ApplicationFiled: March 22, 2013Publication date: August 22, 2013Applicant: Helix BioPharma Corp.Inventors: Marianna FOLDVARI, Praveen KUMAR, John M. DOCHERTY
-
Patent number: 8512690Abstract: The present application describes organic compounds that are useful for the treatment, prevention and/or amelioration of human diseases.Type: GrantFiled: April 7, 2010Date of Patent: August 20, 2013Assignee: Novartis AGInventors: Trixi Brandl, Prakash Raman, Pascal Rigollier, Mohindra Seepersaud, Oliver Simic
-
Publication number: 20130209394Abstract: The invention is based upon the discovery that the EGFR pathway can stimulate a previously unknown tumorigenic function of CA IX, via phosphorylation of the sole tyrosine residue present in CA IX's intracellular domain. EGFR-phosphorylated CA IX then interacts with the p85 subunit of PI3K to activate Akt, which in turn is associated with anti-apototic function and increased cell survival. The latter finding indicates that there is a positive feedback loop for CA9 expression mediated by the PI3K pathway in preneoplastic/neoplastic diseases. Disclosed herein are novel therapeutic methods for treating preneoplastic/neoplastic diseases associated with abnormal MN/CA IX expression, using EGFR pathway inhibitors. Preferably, the EGFR pathway inhibitors are tyrosine kinase inhibitors or EGFR-specific antibodies.Type: ApplicationFiled: February 2, 2012Publication date: August 15, 2013Inventor: Thambi DORAI
-
Publication number: 20130209402Abstract: The present invention relates to human papillomavirus E7 antigen compounds and compositions for treating human papillomavirus infection and associated conditions. The invention provides, in part, polypeptide and nucleic acid molecules including sequences substantially identical to the sequences of two or more human papillomavirus (HPV) E7 antigens, where the E7 antigens are selected from at least two different HPV strains, and methods of using the same.Type: ApplicationFiled: July 15, 2011Publication date: August 15, 2013Applicant: BRITISH COLUMBIA CANCER AGENCY BRANCHInventors: John R. Webb, Darin Arne Wick